Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combating Alzheimer’s and Parkinson’s Disease with Novel Antibodies

05.12.2012
Novel Antibodies for Combating Alzheimer’s and Parkinson’s Disease

Researchers at Rensselaer Polytechnic Institute Develop Antibodies With Improved Ability for Preventing Formation of Toxic Protein Particles Linked to Diseases Including Alzheimer’s and Parkinson’s

Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer’s disease and Parkinson’s disease, as well as Type 2 diabetes, according to a new study.

The onset of these devastating diseases is associated with the inappropriate clumping of proteins into particles that are harmful to cells in the brain (Alzheimer’s disease and Parkinson’s disease) and pancreas (Type 2 diabetes). Antibodies, which are commonly used by the immune system to target foreign invaders such as bacteria and viruses, are promising weapons for preventing the formation of toxic protein particles. A limitation of conventional antibodies, however, is that high concentrations are required to completely inhibit the formation of toxic protein particles in Alzheimer’s, Parkinson’s, and other disorders.

To address this limitation, a team of researchers led by Rensselaer Professor Peter Tessier has developed a new process for creating antibodies that potently inhibit formation of toxic protein particles. Conventional antibodies typically bind to one or two target proteins per antibody. Antibodies created using Tessier’s method, however, bind to 10 proteins per antibody. The increased potency enables the novel antibodies to prevent the formation of toxic protein particles at unusually low concentrations. This is an important step toward creating new therapeutic molecules for preventing diseases such as Alzheimer’s and Parkinson’s.

“It is extremely difficult to get antibodies into the brain. Less than 5 percent of an injection of antibodies into a patient’s blood stream will enter the brain. Therefore, we need to make antibodies as potent as possible so the small fraction that does enter the brain will completely prevent formation of toxic protein particles linked to Alzheimer’s and Parkinson’s disease,” said Tessier, assistant professor in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer. “Our strategy for designing antibody inhibitors exploits the same molecular interactions that cause toxic particle formation, and the resulting antibodies are more potent inhibitors than antibodies generated by the immune system.”

Results of the new study, titled “Rational design of potent domain antibody inhibitors of amyloid fibril assembly,” were published online last week by the journal Proceedings of the National Academy of Sciences (PNAS). The study may be viewed at: http://www.pnas.org/content/early/2012/11/14/1208797109.abstract

This research was conducted in the laboratories of the Center for Biotechnology and Interdisciplinary Studies at Rensselaer.

Tessier’s research represents a new way of generating therapeutic antibodies. Currently, most antibodies are obtained by exploiting the immune system of rodents. Mice are injected with a target protein, for example the Alzheimer’s protein, and the animal’s immune system generates an antibody specific for the target protein. Tessier’s method is radically different as it relies on rational design approaches to create antibodies based on properties of the target proteins.

Along with Tessier, co-authors of the paper are Rensselaer graduate students Ali Reza Ladiwala, Moumita Bhattacharya, Joseph Perchiaccaa; Ping Cao and Daniel Raleigh of the Department of Chemistry at Stony Brook University; Andisheh Abedini and Ann Marie Schmidt of the Diabetes Research Program at New York University School of Medicine; and Jobin Varkey and Ralf Langen of the Zilkha Neurogenetic Institute at the University of Southern California, Los Angeles.

This study was funded with support from the American Health Assistance Foundation, the National Science Foundation, the Pew Charitable Trust, and the National Institutes of Health.

For more information on Tessier and his research at Rensselaer, visit:

• Tessier Lab Website
http://www.rpi.edu/~tessip
• Researchers Design Alzheimer’s Antibodies
http://news.rpi.edu/update.do?artcenterkey=2959
• Research From Rensselaer Professor Offers Clues to Alzheimer’s Disease
http://news.rpi.edu/update.do?artcenterkey=2743
• Rensselaer Professor Peter M. Tessier Named Pew Scholar
http://news.rpi.edu/update.do?artcenterkey=2740
• Rensselaer Professor Peter Tessier Receives NSF CAREER Award
http://news.rpi.edu/update.do?artcenterkey=2693
Contact
Michael Mullaney
Rensselaer Polytechnic Institute
Troy, NY
518-276-6161
mullam@rpi.edu
www.rpi.edu/news
Visit the Rensselaer research and discovery blog: http://approach.rpi.edu
Follow us on Twitter: www.twitter.com/RPInews

Michael Mullaney | Newswise
Further information:
http://www.rpi.edu/news

More articles from Life Sciences:

nachricht A "GPS" for molecules
19.12.2014 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Trigger mechanism for recovery after spinal cord injury revealed
19.12.2014 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

Smart Cities

08.12.2014 | Event News

European Polymer Congress 2015 in Dresden/Germany

01.12.2014 | Event News

Regional economic cooperation in Central Asia

21.11.2014 | Event News

 
Latest News

Trade Winds ventilate the Tropical Oceans

19.12.2014 | Earth Sciences

Quantum physics just got less complicated

19.12.2014 | Physics and Astronomy

Europe shows that humans and large predators can share the same landscape

19.12.2014 | Ecology, The Environment and Conservation

VideoLinks
B2B-VideoLinks
More VideoLinks >>>